title: Biosimilars encircle Rituxan, US debates innovator exclusivity.
authors.forename: Karen
authors.initials: K
authors.lastname: Carey
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D018795:Device Approval; D017277:Drug Approval; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D006801:Humans; D012216:Rheumatic Diseases / Q000188:drug therapy*; D000069283:Rituximab; D013810:Therapeutic Equivalency; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069283:Rituximab